Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2007 3
2009 3
2010 3
2013 1
2016 1
2017 1
2020 1
2021 1
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
Martin M, Hegg R, Kim SB, Schenker M, Grecea D, Garcia-Saenz JA, Papazisis K, Ouyang Q, Lacko A, Oksuzoglu B, Reeves J, Okera M, Testa L, Shimizu C, Denduluri N, Adamchuk H, Dakhil S, Wei R, Forrester T, Fernandez MM, Zimmermann A, Headley D, Johnston SRD. Martin M, et al. Among authors: lacko a. JAMA Oncol. 2022 Aug 1;8(8):1190-1194. doi: 10.1001/jamaoncol.2022.1488. JAMA Oncol. 2022. PMID: 35653145 Free PMC article. Clinical Trial.
Over-treatment in metastatic breast cancer.
Senkus E, Łacko A. Senkus E, et al. Among authors: lacko a. Breast. 2017 Feb;31:309-317. doi: 10.1016/j.breast.2016.06.024. Epub 2016 Jul 21. Breast. 2017. PMID: 27453572 Review.
Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.
Borstnar S, Palacova M, Łacko A, Timcheva C, Gal-Yam EN, Papazisis K, Beniak J, Kudela P, Rubovszky G. Borstnar S, et al. Among authors: lacko a. Radiol Oncol. 2022 May 17;56(2):238-247. doi: 10.2478/raon-2022-0020. Radiol Oncol. 2022. PMID: 35575587 Free PMC article. Clinical Trial.
High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast cancer: results of comprehensive re-evaluation of multi-institutional case series.
Kunc M, Pęksa R, Cserni G, Iżycka-Świeszewska E, Łacko A, Radecka B, Braun M, Pikiel J, Litwiniuk M, Pogoda K, Szwajkosz A, Biernat W, Senkus E. Kunc M, et al. Among authors: lacko a. Pathology. 2022 Apr;54(3):269-278. doi: 10.1016/j.pathol.2021.10.003. Epub 2022 Jan 21. Pathology. 2022. PMID: 35074178 Free article.
[Cardiac toxicity in cancer therapy].
Łacko A, Włodarska I, Zymliński R, Mazur G, Wróbel T, Gisterek I. Łacko A, et al. Pol Merkur Lekarski. 2002 Jul;13(73):79-85. Pol Merkur Lekarski. 2002. PMID: 12362515 Review. Polish.
microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers is Mainly Dependent on HER2 Status-A Pilot Study.
Kunc M, Popęda M, Niemira M, Szałkowska A, Bieńkowski M, Pęksa R, Łacko A, Radecka BS, Braun M, Pikiel J, Litwiniuk M, Pogoda K, Iżycka-Świeszewska E, Krętowski A, Żaczek AJ, Biernat W, Senkus-Konefka E. Kunc M, et al. Among authors: lacko a. Diagnostics (Basel). 2020 Aug 20;10(9):617. doi: 10.3390/diagnostics10090617. Diagnostics (Basel). 2020. PMID: 32825530 Free PMC article.
Serum vascular endothelial growth factors a, C and d in human breast tumors.
Gisterek I, Matkowski R, Lacko A, Sedlaczek P, Szewczyk K, Biecek P, Halon A, Staszek U, Szelachowska J, Pudelko M, Bebenek M, Harlozinska-Szmyrka A, Kornafel J. Gisterek I, et al. Among authors: lacko a. Pathol Oncol Res. 2010 Sep;16(3):337-44. doi: 10.1007/s12253-009-9211-8. Epub 2009 Oct 11. Pathol Oncol Res. 2010. PMID: 19821158 Free article.
16 results